• Sino Biopharmaceutical said its MSCI ESG Rating was upgraded to AA from A.
• The company said its ESG governance framework is led by the board and organized around a “CARE” strategy covering Cure, Accessible, Relationship, and Environmental.
• It said pollutant emission intensity for multiple major pollutants has declined by more than 10% annually for five consecutive years.
• The company reported cumulative R&D spending of more than RMB13 billion over the past three years.
• It said it made more than RMB150 million in donations over the past three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12062958), on March 23, 2026, and is solely responsible for the information contained therein.